MCL1 and osteosarcoma: Targeting MCL1 in osteosarcoma shows therapeutic potential and may be a viable strategy for canine and human clinical trials, as dogs are an established model of spontaneous osteosarcoma and their MCL1 protein is highly homologous to humans [39–49].